Bristol Myers Squibb's big buys: $18.1 billion in 2 biotech deals Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to ...

Now with these positive data in hand, we are focused on our NDA submission to the FDA expected in the third quarter of 2026" (President, CEO & Director Mortimer). "Our base case assumption is a ...